Gemcitabine is a cancer drug used to treat solid tumors as well as certain blood cancers. It can be administered alone or in combination with other drugs as part of a chemotherapy regimen. The genetic variants hypothesized to play a role in the variability of patient response to gemcitabine as well as those genetic variants that may influence severity of adverse events are summarized.
Click on the picture to view the pathway
Read the publication: PharmGKB summary: gemcitabine pathway
Alvarellos ML, Lamba J, Sangkuhl K, Thorn CF, Wang L, Klein DJ, Altman RB, Klein TE.
Pharmacogenetics and Genomics. Advanced online publication. 2014 August 26 doi: 10.1097/FPC.0000000000000086